Johnson & Johnson - Net Worth and Insider Trading
Johnson & Johnson Net Worth
The estimated net worth of Johnson & Johnson is at least $205 Million dollars as of 2024-05-05. Johnson & Johnson is the 10% Owner of Fusion Pharmaceuticals Inc and owns about 3,670,516 shares of Fusion Pharmaceuticals Inc (FUSN) stock worth over $79 Million. Johnson & Johnson is the 10% Owner of Protagonist Therapeutics Inc and owns about 2,449,183 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $64 Million. Johnson & Johnson is also the 10% Owner of CVRx Inc and owns about 4,103,430 shares of CVRx Inc (CVRX) stock worth over $38 Million. Besides these, Johnson & Johnson also holds Nevro Corp (NVRO) , Minerva Neurosciences Inc (NERV) , Neoleukin Therapeutics Inc (NLTX) , Achillion Pharmaceuticals Inc (ACHN) . Details can be seen in Johnson & Johnson's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Johnson & Johnson has not made any transactions after 2024-02-16 and currently still holds the listed stock(s).
Transaction Summary of Johnson & Johnson
Johnson & Johnson Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Johnson & Johnson owns 18 companies in total, including Fusion Pharmaceuticals Inc (FUSN) , Provention Bio Inc (PRVB) , and Inspire Medical Systems Inc (INSP) among others .
Click here to see the complete history of Johnson & Johnson’s form 4 insider trades.
Insider Ownership Summary of Johnson & Johnson
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
FUSN | Fusion Pharmaceuticals Inc | 2020-06-30 | 10 percent owner |
PRVB | Provention Bio Inc | 2018-07-03 | 10 percent owner |
INSP | Inspire Medical Systems Inc | 2018-05-02 | 10 percent owner |
2017-11-20 | 10 percent owner | ||
2015-03-13 | 10 percent owner | ||
2016-08-16 | 10 percent owner | ||
2015-06-08 | 10 percent owner | ||
2015-08-11 | 10 percent owner | ||
2014-05-01 | 10 percent owner | ||
2014-02-04 | 10 percent owner | ||
2010-12-31 | 10 percent owner | ||
2010-04-14 | 10 percent owner | ||
2007-03-27 | 10 percent owner | ||
2003-12-31 | 10 percent owner | ||
2024-02-16 | 10 percent owner | ||
2022-11-09 | 10 percent owner | ||
2014-02-04 | 10 percent owner | ||
2023-05-03 | 10 percent owner |
Johnson & Johnson Latest Holdings Summary
Johnson & Johnson currently owns a total of 7 stocks. Among these stocks, Johnson & Johnson owns 3,670,516 shares of Fusion Pharmaceuticals Inc (FUSN) as of June 30, 2020, with a value of $79 Million and a weighting of 38.38%. Johnson & Johnson owns 2,449,183 shares of Protagonist Therapeutics Inc (PTGX) as of August 16, 2016, with a value of $64 Million and a weighting of 31.15%. Johnson & Johnson also owns 4,103,430 shares of CVRx Inc (CVRX) as of February 16, 2024, with a value of $38 Million and a weighting of 18.44%. The other 4 stocks Nevro Corp (NVRO) , Minerva Neurosciences Inc (NERV) , Neoleukin Therapeutics Inc (NLTX) , Achillion Pharmaceuticals Inc (ACHN) have a combined weighting of 12.03% among all his current holdings.
Latest Holdings of Johnson & Johnson
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
FUSN | Fusion Pharmaceuticals Inc | 2020-06-30 | 3,670,516 | 21.45 | 78,732,568 |
PTGX | Protagonist Therapeutics Inc | 2016-08-16 | 2,449,183 | 26.09 | 63,899,184 |
CVRX | CVRx Inc | 2024-02-16 | 4,103,430 | 9.22 | 37,833,625 |
NVRO | Nevro Corp | 2015-06-08 | 2,066,740 | 11.29 | 23,333,495 |
NERV | Minerva Neurosciences Inc | 2015-03-13 | 562,520 | 2.37 | 1,333,172 |
NLTX | Neoleukin Therapeutics Inc | 2015-08-11 | 5,000 | 3.49 | 17,450 |
ACHN | Achillion Pharmaceuticals Inc | 2017-11-20 | 0 | 6.76 | 0 |
Holding Weightings of Johnson & Johnson
Johnson & Johnson Form 4 Trading Tracker
According to the SEC Form 4 filings, Johnson & Johnson has made a total of 1 transactions in Fusion Pharmaceuticals Inc (FUSN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Fusion Pharmaceuticals Inc is the acquisition of 725,000 shares on June 30, 2020, which cost Johnson & Johnson around $12 Million.
According to the SEC Form 4 filings, Johnson & Johnson has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the acquisition of 583,333 shares on August 16, 2016, which cost Johnson & Johnson around $7 Million.
According to the SEC Form 4 filings, Johnson & Johnson has made a total of 1 transactions in CVRx Inc (CVRX) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in CVRx Inc is the sale of 3,725 shares on February 16, 2024, which brought Johnson & Johnson around $96,142.
More details on Johnson & Johnson's insider transactions can be found in the Insider Trading History of Johnson & Johnson table.Insider Trading History of Johnson & Johnson
- 1
Johnson & Johnson Trading Performance
GuruFocus tracks the stock performance after each of Johnson & Johnson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Johnson & Johnson is 27.87%. GuruFocus also compares Johnson & Johnson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Johnson & Johnson within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Johnson & Johnson's insider trading performs compared to the benchmark.
Performance of Johnson & Johnson
Johnson & Johnson Ownership Network
Ownership Network List of Johnson & Johnson
Ownership Network Relation of Johnson & Johnson
Johnson & Johnson Owned Company Details
What does Fusion Pharmaceuticals Inc do?
Who are the key executives at Fusion Pharmaceuticals Inc?
Johnson & Johnson is the 10 percent owner of Fusion Pharmaceuticals Inc. Other key executives at Fusion Pharmaceuticals Inc include Chief Medical Officer Dmitri Bobilev , director & Chief Executive Officer John Valliant , and Chief Scientific Officer Christopher P Leamon .
Fusion Pharmaceuticals Inc (FUSN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Fusion Pharmaceuticals Inc (FUSN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Fusion Pharmaceuticals Inc (FUSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Fusion Pharmaceuticals Inc (FUSN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Fusion Pharmaceuticals Inc Insider Transactions
Johnson & Johnson Mailing Address
Above is the net worth, insider trading, and ownership report for Johnson & Johnson. You might contact Johnson & Johnson via mailing address: One Johnson & Johnson Plz, New Brunswick Nj 08933.